The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Open accessAbstract
Mantle cell lymphoma (MCL) is considered incurable. Intensive immunochemotherapy with stem cell support has not been tested in large, prospective series. In the 2nd Nordic MCL trial, we treated 160 consecutive, untreated patients younger than 66 years in a phase 2 protocol with dose-intensified induction immunochemotherapy with rituximab (R) + cyclophosphamide, vincristine, doxorubicin, prednisone (maxi-CHOP), alternating with R + high-dose cytarabine. Responders received high-dose chemotherapy with BEAM or BEAC (carmustine, etoposide, cytarabine, and melphalan/cyclophosphamide) with R-in vivo purged autologous stem cell support. Overall and complete response was achieved in 96% and 54%, respectively. The 6-year overall, event-free, and progression-free survival were 70%, 56%, and 66%, respectively, with no relapses occurring after 5 years. Multivariate analysis showed Ki-67 to be the sole independent predictor of event-free survival. The nonrelapse mortality was 5%. The majority of stem cell products and patients assessed with polymerase chain reaction (PCR) after transplantation were negative. Compared with our historical control, the Nordic MCL-1 trial, the event-free, overall, and progression-free survival, the duration of molecular remission, and the proportion of PCR-negative stem cell products were significantly increased (P < .001). Intensive immunochemotherapy with in vivo purged stem cell support can lead to long-term progression-free survival of MCL and perhaps cure. Registered at www.isrctn.org as #ISRCTN 87866680.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,625
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Rosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M., Campo, E., Gascoyne, R. D., Grogan, T. M., Muller-Hermelink, H. K., Smeland, E. B., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00028-x · Cited by 914
Self-citationLenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.133 · Cited by 574
Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.1825 · Cited by 557
Forstpointner, R., Unterhalt, M., Dreyling, M., Bock, H.-P., Repp, R., Wandt, H., Pott, C., Seymour, J. F., Metzner, B., Hanel, A., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016725 · Cited by 467
Cited by
Shankland, K. R., Armitage, J. O., & Hancock, B. W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60605-9 · Cited by 641
Goy, A., Sinha, R., Williams, M. E., Kalayoglu Besisik, S., Drach, J., Ramchandren, R., Zhang, L., Cicero, S., Fu, T., & Witzig, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2835 · Cited by 349
Sureda, A., Bader, P., Cesaro, S., Dreger, P., Duarte, R. F., Dufour, C., Falkenburg, J. H. F., Farge-Bancel, D., Gennery, A., Kröger, N., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.6 · Cited by 337
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Witzig, T. E., Reeder, C. B., LaPlant, B. R., Gupta, M., Johnston, P. B., Micallef, I. N., Porrata, L. F., Ansell, S. M., Colgan, J. P., Jacobsen, E. D., et al. (2011) · Leukemia · doi:10.1038/leu.2010.226 · Cited by 297
Pott, C., Hoster, E., Delfau-Larue, M.-H., Beldjord, K., Böttcher, S., Asnafi, V., Plonquet, A., Siebert, R., Callet-Bauchu, E., Andersen, N., et al. (2010) · Blood · doi:10.1182/blood-2009-06-230250 · Cited by 272
Self-citation
Metadata
- Authors
- Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B., Jerkeman, M., Eriksson, M., Nordström, M., Kimby, E., Boesen, A. M., Kuittinen, O., Lauritzsen, G. F., Nilsson-Ehle, H., Ralfkiær, E., Åkerman, M., Ehinger, M., Sundström, C., Langholm, R., Delabie, J., Karjalainen-Lindsberg, M.-L., Brown, P., Elonen, E., & for the Nordic Lymphoma Group
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-10-01
- Volume
- 112
- Issue
- 7
- Pages
- 2687-2693
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2124235514
- Cited by
- 622
- References
- 16
- FWCI
- 28.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. https://app.cochat.ai/papers/10.1182/blood-2008-03-147025
- The paper
- Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B., Jerkeman, M., Eriksson, M., Nordström, M., Kimby, E., Boesen, A. M., Kuittinen, O., Lauritzsen, G. F., Nilsson-Ehle, H., Ralfkiær, E., Åkerman, M., Ehinger, M., Sundström, C., Langholm, R., Delabie, J., . . . for the Nordic Lymphoma Group. (2008). Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. https://doi.org/10.1182/blood-2008-03-147025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
